|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.
|
31376137 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The receptors for HER2 are overexpressed in various human cancers, such as breast and ovarian cancer.
|
31470531 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aim of the multicenter study is to investigate the correlation between the expression of estrogen alpha receptors (ERα), progesterone receptors (PR), human epidermal growth factor receptor 2 (HER2), stromal cell-derived factor 1 (SDF1) and its receptor C-X-C chemokine receptor type 4 (CXCR4), breast cancer metastasis suppressor 1 (BRMS1), astrocyte elevated gene 1 (AEG1), depending on the status of BRCA1 protein, in patients suffering from OC and BC with brain metastases.
|
30822630 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HER2/HER3 and clinical feature of ovarian cancer.
|
31328457 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
HER2 amplifications and overexpression in ovarian cancer are reported to vary, and responses to HER2 inhibitors have been poor.
|
30499260 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, analyses that considered all 41 genes with clinical variables together identified genes TLR4, BSCL2, CDH1, ERBB2, BRCA2 and SCGB2A1 as independently related to survival in OC.
|
31655274 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, HER2 protein is over-expressed in epithelial ovarian cancer tissues, and trastuzumab exerts anti-tumor effect by inhibiting cell proliferation and inducing apoptosis, suggesting it might be a novel approach for the treatment of ovarian cancer.
|
30509111 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
In order to assess the validity of ErbB2-targeted therapy in ovarian cancer, we investigated the effectiveness of two FDA-approved tyrosine kinase inhibitors of ErbB2, lapatinib and neratinib, on the growth of ovarian cancers.
|
31689531 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy.
|
30856589 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
We used six whole-exome-sequenced primary HGSOC/USC cell-lines and three xenografts overexpressing HER2/neu and harboring mutated or wild-type PIK3CA/PIK3R1 genes to evaluate the role of PI3K-mutations as potential mechanism of resistance to afatinib, an FDA-approved pan-c-erb-inhibitor in clinical trials in USC.
|
30630630 |
2019 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Aberrant <i>EGFR</i> expression and <i>ERBB2/3/4</i> mRNA levels were associated with OC prognosis.
|
30588099 |
2018 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
HER2-targeting properties and biodistribution were evaluated in BALB/C <i>nu/nu</i> mice bearing ovarian carcinoma cell (SKOV-3) xenografts.
|
28864631 |
2018 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
The prognostic role of human epidermal growth factor receptor 2 (HER2) in ovarian cancer has been investigated in previous studies, but the results remain controversial.
|
29381731 |
2018 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis.
|
29535531 |
2018 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
HER2 is a member of epidermal factor receptor (EGFR) family which is overexpressed in breast cancer, ovarian cancer and gastric cancer.
|
30225583 |
2018 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The data demonstrate that the growth of xenografts of human ovarian cancer with high expression of HER2 could be inhibited effectively by Ad-HER2-siRNA+DDP.
|
30052070 |
2018 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Neratinib inhibits xenograft growth and improves overall survival in HER2/neu-amplified ovarian cancer in vivo.Clinical trials are warranted.
|
28397106 |
2017 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PET imaging and biodistribution studies in subcutaneous models of ovarian cancer were performed for non-invasive in vivo evaluation of HER2 expression.
|
28265738 |
2017 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our study showed that the expressions of HER2, STAT3, and SOCS3 are associated with the progression of OC, and higher expressions of HER2 and STAT3 and lower expression of SOCS3 predict poor prognosis of OC.
|
28448787 |
2017 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
HER2 is overexpressed in 20-25% of breast and ovarian cancers.
|
27693491 |
2017 |
|
Malignant neoplasm of ovary
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Association of HER2 codon 655 polymorphism with ovarian cancer.
|
26666819 |
2016 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results demonstrated that Gigantoxin-4-4D5 scFv exerted a highly cytotoxic effect on the HER2/neu-positive ovarian carcinoma SK-OV-3 cell line.
|
27063011 |
2016 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins.
|
26436696 |
2015 |
|
Malignant neoplasm of ovary
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to investigate the potential prognostic value of SKP2, genes P27Kip1, K-ras, c-Myc, COX2 and HER2 genes expression in ovarian cancer.
|
26320455 |
2015 |
|
Malignant neoplasm of ovary
|
0.700 |
Biomarker
|
disease |
BEFREE |
Together, these data indicate that HER2 represents an important oncogene in ovarian cancer, and suggest that targeting this tyrosine kinase with T-DM1 may be therapeutically effective, especially in ovarian tumors with high content of HER2.
|
26336133 |
2015 |